Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

The purpose of this study is to evaluate the safety and efficacy of nivolumab, or nivolumab in combination with azacitidine in participants with recurrent, resectable osteosarcoma

cancer chemotherapy
resectable osteosarcoma
metastasis
metastatic disease
azacitidine
  • 37 views
  • 05 Jun, 2022
  • 22 locations
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

This phase I trial is to find out the best dose, possible benefits and/or side effects of magrolimab in combination with dinutuximab in treating patients with neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory) or relapsed osteosarcoma. Magrolimab and dinutuximab are monoclonal antibodies that may …

  • 0 views
  • 14 Jun, 2022
  • 7 locations
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

This study is a open-lable, , single center, phase II clinical study. Target population is patients with locally resectable osteosarcoma. Study objective is to compare the efficacy and safety of

ifosfamide
methotrexate
measurable disease
adriamycin
monoclonal antibodies
  • 0 views
  • 28 Feb, 2022
  • 1 location
Olaparib With Ceralasertib in Recurrent Osteosarcoma

This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: Olaparib Ceralasertib

neulasta
measurable disease
recurrent osteosarcoma
blood transfusion
kidney function tests
  • 16 views
  • 21 Oct, 2021
  • 2 locations
ICONIC: Improving Outcomes Through Collaboration in OsteosarComa (ICONIC)

There has been little improvement in outcome for patients with osteosarcoma (OS) over the last 20 years. There have been only a few clinical trials of new treatments and no major new therapies introduced recently. This is in part because there is no good understanding of the biology of osteosarcoma, …

  • 1 views
  • 23 Mar, 2022
  • 18 locations